Montpellier, October 5, 2023 – French medical robotics company Quantum Surgical has been awarded the 2023 JFR Innovation Prize in the ‘Interventional Imaging’ category for its Epione® robot. Presented by the French Society of Radiology and Medical Imaging, this award recognizes industry leaders who bring innovations to various areas of diagnostic and interventional medical imaging. Epione® enables early and minimally invasive treatment of abdominal and lung tumors. Quantum Surgical will participate in the Francophone Radiology Days (JFR) from October 13 to 16, 2023, at the Palais des Congrès in Paris.
Quantum Surgical’s flagship product, the Epione® robotic platform is dedicated to the curative treatment of cancers. Epione® allows physicians to treat inoperable tumors in the liver, kidney, pancreas and lung. Over 250 patients have already been treated in France and the United States.
The French Society of Radiology and Medical Imaging (SFR) has just awarded Quantum Surgical the 2023 JFR Innovation Prize in the ‘Interventional Imaging’ category for Epione®, its robotic solution for percutaneous multi-needle ablation of tumors located in the abdomen and lungs. Compatible with various ablation technologies, the Epione® solution standardizes the complex process of multi-needle placement and insertion by integrating specific functionalities into its software.
This allows for easier planning (based on a range of patterns predefined by the ablation needle manufacturer), precise targeting of complex tumors with accurate positions and oblique trajectories, and reduced needle insertion time thanks to automated robot arm positioning. Needles can then be placed with a reduced number of scans, limiting radiation exposure.
“We are very proud to receive the 2023 JFR Innovation Prize. At Quantum Surgical, we continuously develop features that improve both the user experience for practitioners and that of the patients. We work hand in hand with healthcare professionals to better understand their needs and evolve our Epione® robot to meet them as effectively as possible,” says Bertin Nahum, President, and Co-founder of Quantum Surgical.
Epione® is a robotic-assisted percutaneous ablation system, using a robotic arm, a navigation system and a camera. This procedure is an alternative to surgery in which a needle is inserted through the skin to the tumor to destroy it. This technique makes it possible to treat tumors that are particularly difficult to reach, due to their size or their location.
Relying on the know-how of the practitioner, Epione® integrates all the steps of a percutaneous ablation procedure in a single platform: planning, targeting, ablation, confirmation.
A demonstration video of the Epione® robot is available here.
Quantum Surgical will participate in the Francophone Radiology Days from October 13 to 16, 2023, at the Palais des Congrès in Paris, located at Stand No. 14, 3rd floor, Interventional Radiology Village. The Innovation JFR Awards ceremony will take place on October 15 at 12:45 PM.
About Quantum Surgical
Quantum Surgical is a French medical robotics company based in Montpellier. As a key player in health innovation, Quantum Surgical develops concrete solutions to the major public health problem that cancer is.
Its Epione® robotic percutaneous ablation platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments.
The Epione® device is CE marked for abdomen and lung tumors, and FDA cleared for abdominal tumors. More than 250 patients have already been treated worldwide.
Co-founded in 2017 and with a team of 100+ employees, Quantum Surgical is based in Montpellier, with an international reach. Quantum Surgical received the Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research.
More information: www.quantumsurgical.com
Press contact Quantum Surgical
Stéphanie Moy
s.moy@quantumsurgical.com
Tel. : +33 (0)6 32 55 85 48
